INTERNATIONAL WORKSHOP ON CLINICAL PHARMACOLOGY … · Future: 40 years of Clinical Pharmacology)...

www.virology-education.com

EVALUATION REPORT

17TH INTERNATIONAL WORKSHOP ON

HIVHepatitis

WASHINGTON DC, USA • 8 - 10 JUNE 2016

CLINICAL PHARMACOLOGYOF HIV & HEPATITIS THERAPY

HIVHepatitis

2EVALUATION REPORT 17th International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy 8 - 10 June 2016, Washington, DC, USA

EXECUTIVE SUMMARY

The 17TH INTERNATIONAL WORKSHOP ON CLINICAL PHARMACOLOGY OF HIV & HEPATITIS THERAPY was held on 8-10 June 2016 at the Washington Plaza Hotel and was attended by nearly 160 participants from 20 countries. The meeting gathers a steady international community of researchers and healthcare professionals.

Professional background of the participants is reflected in the below chart:

Professional Background

Pharmacologist; 43%

Pharmacist; 20%

Researcher; 19%Other; 8%

Cl inician; 6%

Student; 5%

Marketing person; 1%

IMPACT97% of the respondents indicated that the content of the workshop increased their knowledge, and 83% indicated that the workshop is beneficial for the clinical management of their patients. Furthermore, 86% of the respondents indicated that they intend to incorporate the new information into their daily practice after attending the workshop.

On average, 90% of the respondents indicated that the learning objectives were met.

PROGRAMThe program included 25 invited lectures, 15 oral abstract presentations, three poster viewing sessions, a pro-con debate and two roundtable discussions. Ample time was allocated for discussion. Just as last year, 3/4 day was dedicated to Hepatitis C resistance, by way of incorporating the 11th International Workshop on Hepatitis C: Resistance and New Compounds. The presentation of, Dr Catia Marzolini entitled “Will we see the Back of DDIs” (Back to the Future: 40 years of Clinical Pharmacology) received the highest score (an average of 4,5 (out of 5)) on all categories.

GENERAL MEETING SCORE98% of the participants rated the meeting experience as excellent/good. 96% would recommend this meeting to their peers and 89% intend to attend next year.

The Organizing Committee and the Organizing Secretariat are pleased with the evaluation results of the 17th edition of this meeting and are looking forward to an even more successful edition in 2017!

“Best meeting I go to each year”

HIVHepatitis


CONTENT

Executive Summary .............................................................................. 2

Introduction ........................................................................................... 4

Meeting Partners .................................................................................. 6

Corporate Supporters ........................................................................... 7

Program Committee ............................................................................. 8

Organizing Committee .......................................................................... 9

Scientific Committee ...........................................................................10

Industry Liaison Board ........................................................................11

Participants’ Feedback ........................................................................12

Meeting Demographics ........................................................................17

Conclusion ...........................................................................................18

List of Participants ...............................................................................19

HIVHepatitis


INTRODUCTION

This is the evaluation report of the 17th International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy, held on 8 - 10 June 2016 at the Washington Plaza Hotel in Washington DC, USA. The Organizing Commitee and the Organizing Secretariat highly value the opinion of the participants in order to further improve the quality of the workshop. Participants were asked to complete an evaluation form to share their opinion on several subjects.

BACKGROUNDUnderstanding the clinical pharmacology of antiretroviral therapy is pivotal to designing optimal treatment and prevention strategies for HIV & Hepatitis infection. Drug exposure is significantly influenced by drug interactions, medication taking behavior, and patients’ physiologic and genetic characteristics. These factors are central to determining therapeutic efficacy, failure or toxicity. Despite great progress, many pharmacologic challenges still exist.

The workshop provides a platform for state-of-the-art discussions of current topics fundamental to the optimal use of antiretroviral therapy including drug-drug interactions, pharmacokinetics of investigational agents and existing drugs, pharmacodynamics, drug dosing in special populations, post-marketing surveillance project, and regulatory considerations.

MEETING OBJECTIVES• To gather experts involved in clinical pharmacology from different disciplines in an interactive workshop setting

• To provide a platform for presentation and discussion of the latest developments in the field

• To map all current studies and results

• To translate new data to treatment guidelines

• To stimulate discussion and consensus on best practice

FORMATThis meeting consists of invited lectures, abstract-driven presentations, roundtable discussions, clinical case presentations and poster viewing sessions.

The meeting is abstract-driven. It is known as an excellent platform for young investigators to present their research. To ensure the quality of accepted abstracts, all submitted abstracts go through a blind, peer-reviewed process conducted by the members of the Program Committee, the Organizing Committee and the Scientific Committee.

UNIQUE MEETING FEATURESThe International Workshop on Clinical Pharmacology on HIV & Hepatitis:

• Is the premier Clinical Pharmacology meeting in the world

• Has a strong community of clinical pharmacologists and other healthcare professionals involved in this field

• Is an independent scientific platform for discussion and debate

TARGET AUDIENCEThe target audience of this workshop consist of experts in HIV and Hepatitis, clinical pharmacologists, pharmacists, educated clinicians, industry representatives, government representatives, PhD students and others involved in clinical pharmacology of HIV and Hepatitis therapy.

HIVHepatitis


INTRODUCTION

HIVHepatitis


MEETING PARTNERS

ACADEMIC PARTNERS

RELATED EVENTS

ASSOCIATED WEBSITES

ENDORSED BY

University of Torino

HIVHepatitis


CORPORATE SUPPORTERS

PLATINUM LEVEL

SILVER LEVEL

SUPPORTER LEVEL

The organizers acknowledge the contributions of our corporate supporters that have made the 17TH INTERNATIONAL WORKSHOP ON CLINICAL PHARMACOLOGY OF HIV & HEPATITIS THERAPY possible:

HIVHepatitis


PROGRAM COMMITTEE

CHARLES BOUCHER, MD, PhD Erasmus Medical Center The Netherlands

CHARLES FLEXNER, MD Johns Hopkins University USA

DAVID BACK, PhD University of Liverpool United Kingdom

DAVID BURGER, PharmD, PhD Radboud University Nijmegen The Netherlands

TERRENCE BLASCKE, MD Stanford University School of Medicine USA

COURTNEY FLETCHER, PharmD University of Nebraska Medical Center USA

GIOVANNI DI PERRI, MD, PhD University of Torino Italy

ANGELA KASHUBA, PharmD UNC Chapel Hill USA

HIVHepatitis


ORGANIZING COMMITTEE

JÜRGEN ROCKSTROH, MD, PhD University of Bonn Germany

JENNIFER KISER, PharmD University of Colorado Health Sciences Center USA

SHIRLEY SEO, PhD Food and Drug Administration USA

JEAN-MICHEL PAWLOTSKY, MD, PhD Hôpital Henri Mondor, Université Paris XII France

JONATHAN SCHAPIRO, MD Sheba Medical Centre Israel

HIVHepatitis


SCIENTIFIC COMMITTEE

Peter Anderson ..........................................................................University of Colorado, Denver, USA

Marta Boffito ..............................................................................St. Stephen’s Center, United Kingdom

Stefano Bonora ..........................................................................University of Torino, Italy

Tim Cressey ...............................................................................Chiang Mai University, Thailand

Rodolphe Garraffo ......................................................................Hopital Pasteur Nice, France

David Haas .................................................................................Vanderbilt University Medical Center, USA

Saye Khoo...................................................................................University of Liverpool, United Kingdom

Michael Kurowski.......................................................................Auguste-Victoria Hospital, Germany

Mohammed Lamorde ................................................................Infectious Diseases Institute, Uganda

Jacob Langness .........................................................................University of Colorado Hospital, USA

Lawrence Lee .............................................................................National University of Singapore, Singapore

Helen, McIlleron.........................................................................University of Cape Town, South Africa

José Moltó ..................................................................................Hospital Universitari Germans Trias i Pujol, Spain

Gilles Peytavin ............................................................................Bichat-Cl. Bernard Hospital, France

Elizabeth Phillips .......................................................................Royal Perth Hospital, Australia

Kellie Reynolds ..........................................................................Food and Drug Administration, USA

Kimberly Scarsi ..........................................................................University of Nebraska, USA

Kimberly Struble ........................................................................Food and Drug Administration, USA

Steve Taylor ................................................................................Heartland Hospital, United Kingdom

Alice Tseng .................................................................................Toronto General Hospital, Canada

Stefan Zeuzem ...........................................................................University of Frankfurt, Germany

HIVHepatitis


INDUSTRY LIAISON BOARD

Tim Eley ......................................................................................BMS, USA

Daria Hazuda .............................................................................Merck, USA

Thomas Kakuda .........................................................................Alios BioPharma, USA

Charles La Porte ........................................................................Jansen Biologics, USA

Anita Mathias .............................................................................Gilead, USA

John McHutchison .....................................................................Gilead, USA

Rajeev Menon .............................................................................Abbvie, USA

Parul Patel .................................................................................ViiV Healthcare, USA

Stephen Piscitelli .......................................................................Roivant Sciences, USA

Manoli Vourvahis ........................................................................Pfizer, USA

HIVHepatitis


PARTICIPANTS’ FEEDBACK

MEETING OBJECTIVESStrongly

agree

Agree Average Disagree (Strongly)

disagree

To gather experts involved in clinical pharmacology from different disciplines in an interactive workshop

setting

58% 40% 2% 0% 0%

To provide a platform for presentation and discussion of the latest developments in the field

58% 38% 4% 0% 0%

To map all current studies and results 44% 37% 17% 2% 0%

To translate new data to treatment guidelines 29% 31% 34% 6% 0%

To stimulate discussion and consensus on best practice

36% 53% 11% 0% 0%

GENERAL EVENT EXPERIENCEExcellent /

strongly agree

Good /agree Fair /neutral Fair /disagree Poor /

strongly

disagree

Overall event experience 54% 44% 2% 0% 0%

Opportunity of networking 53% 43% 4% 0% 0%

Content of the conference 43% 49% 8% 0% 0%

Time allocation for discussion 43% 49% 6% 2% 0%

Time allocation per presentation 55% 41% 4% 0% 0%

No commercial bias (product selling) perceived 55% 29% 12% 4% 0%

I would recommend this meeting to my peers 55% 41% 4% 0% 0%

I plan to attend this meeting next year 50% 39% 11% 0% 0%

HIVHepatitis



LECTURES

WEDNESDAY 8 JUNE

Opening session

Opening Lecture: Other Viruses: using Wolbachia to interrupt transmission of viral infections such as Dengue, Chikungunya and Zika Steven Kern, PhD - Bill & Melinda Gates Foundation, USA

Excellent Good Average Fair Poor

Interesting 56% 35% 7% 2% 0%

Relevance 19% 17% 30% 13% 21%

Performance 50% 46% 4% 0% 0%

THURSDAY 9 JUNE

Session 1: Pharmacokinetics in infants and young children

Abstract-driven presentations Excellent Good Average Fair Poor

Interesting 52% 42% 4% 0% 2%

Relevance 46% 35% 13% 6% 0%

Session 2: Hepatitis resistance and pharmacokinetics of DAAs

Role of Resistance Testing Shyam Kottilil, MBBS, PhD - Institute of Human Virology, University of Maryland, USA


Interesting 51% 41% 8% 0% 0%

Relevance 31% 31% 24% 8% 6%

Performance 41% 51% 6% 2% 0%

The FDA Perspective on Hepatitis C Drug Resistance Patrick Harrington, PhD - U.S. Food and Drug Administration, USA


Interesting 51% 45% 4% 0% 0%

Relevance 36% 34% 19% 6% 5%

Performance 47% 51% 2% 0% 0%


Interesting 47% 47% 6% 0% 0%

Relevance 38% 38% 16% 4% 4%

Session 3: Compartmental penetration of Antiretrovirals


Interesting 44% 49% 7% 0% 0%

Relevance 32% 56% 12% 0% 0%

HIVHepatitis



Session 4: Long Acting Antivirals

Target Concentrations Angela Kashuba, PharmD - University of North Carolina, Chapel Hill, USA


Interesting 63% 31% 6% 0% 0%

Relevance 48% 37% 9% 6% 0%

Performance 67% 26% 7% 0% 0%

FDA Perspective on "oral run-in" phase Yodit Belew, MD - U.S. Food and Drug Administration, USA


Interesting 33% 46% 17% 4% 0%

Relevance 33% 33% 17% 8% 9%

Performance 19% 66% 11% 2% 2%

ViiV - Cabotegravir Bill Spreen, PharmD - ViiV Healthcare, USA


Interesting 48% 46% 6% 0% 0%

Relevance 39% 50% 6% 2% 4%

Performance 46% 50% 4% 0% 0%

Janssen - Rilpivirine Herta Crauwels, PhD - Janssen Infectious Diseases, Belgium


Interesting 46% 41% 9% 4% 0%

Relevance 37% 42% 13% 4% 4%

Performance 26% 46% 24% 4% 0%

Abstract-driven Presentations: Excellent Good Average Fair Poor

Interesting 38% 50% 12% 0% 0%

Relevance 35% 46% 13% 0% 6%

Session 5: Back to the Future: 40 years of Clinical Pharmacology

Looking Backwards: Hormonal Contraception and ART Kimberly Scarsi, PharmD, MS, BCPS-ID – University of Nebraska, USA


Interesting 51% 39% 8% 2% 0%

Relevance 35% 37% 22% 6% 0%

Performance 66% 30% 4% 0% 0%

Pharmacogenetics - Back to reality Andrew Owen, PhD, FRSB, FBPhS - University of Liverpool, United Kingdom


Interesting 57% 33% 10% 0% 0%

Relevance 47% 31% 20% 2% 0%

Performance 58% 36% 4% 0% 2%

Will we see the Back of DDIs? Catia Marzolini, PharmD, PhD - University Hospital of Basel, Switzerland


Interesting 59% 33% 8% 0% 0%

Relevance 55% 37% 8% 0% 0%

Performance 61% 33% 6% 0% 0%

The ‘Back Side’ of Compartments Saye Khoo, MD, PhD - University of Liverpool, United Kingdom


Interesting 59% 37% 2% 2% 0%

Relevance 41% 36% 21% 2% 0%

Performance 63% 28% 7% 2% 0%

HIVHepatitis



Back-terial co-infections Mohammed Lamorde, MD, PhD - Infectious Diseases Institute, Uganda


Interesting 53% 45% 0% 2% 0%

Relevance 45% 31% 19% 5% 0%

Performance 56% 37% 5% 2% 0%

Backing up clinical data with modelling Marco Siccardi, PhD - University of Liverpool, United Kingdom


Interesting 62% 31% 5% 2% 0%

Relevance 50% 29% 14% 2% 5%

Performance 67% 26% 5% 2% 0%

FRIDAY 10 JUNESession 6: Clinical Guidance on how to interpret DDI’s

Specific Complex Interactions (mechanic presentation) David Burger, PharmD, PhD – Radboudumc, Nijmegen, The Netherlands


Interesting 62% 33% 5% 0% 0%

Relevance 60% 27% 9% 4% 0%

Performance 58% 40% 0% 2% 0%

Clinical translation of "Amber" Jonathan Schapiro, MD – Sheba Medical Center, Israel


Interesting 62% 38% 0% 0% 0%

Relevance 61% 31% 8% 0% 0%

Performance 54% 31% 15% 0% 0%

Real life cases Elise Smolders – Radboudumc, Nijmegen, The Netherlands


Interesting 50% 33% 13% 2% 2%

Relevance 42% 29% 21% 6% 2%

Session 7: PK/PD of new and existing antivirals: Abstract driven presentations


Interesting 46% 50% 4% 0% 0%

Relevance 40% 46% 14% 0% 0%

Session 8: Clinical Pharmacology Updates on New Compounds (by company rep.)


Interesting 51% 45% 4% 0% 0%

Relevance 50% 45% 5% 0% 0%

Poster Sessions

Poster session were: Excellent Good Average Fair Poor

Valuable 50% 48% 2% 0% 0%

Well

programmed

50% 42% 8% 0% 0%

HIVHepatitis



ORGANIZATIONExcellent Good Average Fair Poor

Content of electronic announcements 34% 49% 17% 0% 0%

Frequency of electronic announcements 29% 50% 15% 6% 0%

Information on coference website 37% 43% 14% 6% 0%

Online registration process 41% 46% 5% 8% 0%

Online abstract submission process 32% 56% 9% 0% 3%

Meeting venue 35% 44% 11% 6% 4%

Meeting room 40% 33% 21% 4% 2%

Audiovisuals 47% 35% 14% 4% 0%

Food & Beverage 50% 35% 11% 4% 0%

Onsite logistics 47% 43% 10% 0% 0%

Service level of Conference Secretariat 50% 38% 10% 2% 0%

PUBLICITYAttention was drawn to this meeting by:

0

5

10

15

20

25

30

35

I knew about this meeting by way of:

Attention was drawn to this meeting by:

0

10

20

30

40

50

60

Scientificprogram

Opportunity tomeet withcolleagues

Experiencefrom previous

meetings

Meetingobjectives

Meetinglocation

Other

I was motivated to attend this meeting by:

HIVHepatitis


MEETING DEMOGRAPHICS

NUMBER OF PARTICIPANTSIn 2016 this meeting had 155 participants from 19 countries. Largest groups were from the United States (86), France (25), United Kingdom (11) and Canada (8).

The geographical distribution of participants is as follows:

USA 86

France 25

United Kingdom 11

Canada 8

The Netherlands 5

Italy 4

Chile 3

Thailand 2

Aruba 1

Australia 1

Belgium 1

China 1

Israel 1

Singapore 1

South Africa 1

Spain 1

Sweden 1

Switzerland 1

Uganda 1

PROFESSIONAL BACKGROUNDMain activity Mainly employed by:

Pharmacologist; 43%

Pharmacist; 20%

Researcher; 19%Other; 8%

Cl inician; 6%

Student; 5%

Marketing person; 1%

University; 34%

Hospital; 30%Industry; 23%

Government; 9%

NGO; 2%

Other; 2%

Area of expertise:

HIV; 53%

Hepatitis; 35%

Other; 12%

HIVHepatitis


CONCLUSION

The overall opinion of the meeting was very positive, as can be deducted from the above scores. Participants were satisfied with the scientific content of the workshop as well as with the logistics and the format of the program. The Organizing Committee and the Organizing Secretariat are very pleased with the evaluation results of this workshop. The success and importance of this workshop have underlined the need for continuation. The 18th edition of the International Workshop on Clinical Pharmacology of Antiviral Therapy is scheduled to take place 14 - 16 June in Chicago, IL, USA.

HIVHepatitis


LIST OF PARTICIPANTS

Last name, name Institute Country

Aboud,Michael ViiV Healthcare United Kingdom

Adkison,Kimberly ViiV Healthcare USA

Anderson,Peter L. University of Colorado Denver USA

Arya,Vikram FDA USA

Au,Stanley FDA USA

Azara,Maria Merck Sharp & Dome (IA) LLC Agencia Chile Chile

Back,David University of Liverpool United Kingdom

Bednasz,Cindy University at Buffalo USA

Berger-De Jong,Inge HOH Aruba

Bernal,Fernando Hospital San Juan de Dios Chile

Bethell,Richard Medivir AB Sweden

Blaschke,Terrence Stanford University School of Medicine USA

Bollen,Pauline D.J. Radboud Universitair Medisch Centrum The Netherlands

Bonora,Stefano University of Torino Italy

Boucher,Charles Erasmus Medical Center The Netherlands

Boussairi,Abdelghani Ch de Saint-Denis France

Brooks,Kristina NIH Clinical Center USA

Burger,David Radboud Universitair Medisch Centrum The Netherlands

Calcagno,Andrea University of Torino Italy

Carole,Jeangirard Janssen France

Chavada,Ruchir Pathology North Australia

Chen,Jingxian University of North Carolina at Chapel Hill USA

Chen,Xinhui University of Colorado USA

Choi,Su-Young the Food and Drug Administration USA

Clarke,Diana Boston Medical Center USA

Colbers,Angela Radboud Universitair Medisch Centrum The Netherlands

Collins,Simon HIV i-Base United Kingdom

Cortes,Claudia University of Chile Chile

Cosler,Patricia Janssen Services, LLC USA

Cotterlaz,Caroline Janssen France

Cottrell,Mackenzie University of North Carolina USA

Crauwels,Herta Janssen Infectious Diseases Belgium

Cressey,Tim Chiang Mai University Thailand

Curley,Paul University of Liverpool United Kingdom

Custodio,Joseph Gilead Sciences USA

D'Amico,Ronald ViiV Healthcare USA

D'Avolio,Antonio University of Turin Italy

De Wet,Joseph Spectrum-health clinic Canada

Di Perri,Giovanni University of Torino Italy

Dickinson,Laura University of Liverpool United Kingdom

Djossou,Felix Centre hospitalier Andrée-Rosemon France

Donovan,Brian ViiV Healthcare USA

HIVHepatitis



Dumond,Julie UNC Eshelman School of Pharmacy USA

Dunnington,Katherine Celerion USA

Eley,Timothy Bristol-Myers Squibb USA

Feng,Hwa-ping Merck USA

Fletcher,Courtney University of Nebraska USA

Flexner,Charles Johns Hopkins University USA

Ford,Susan Parexel International USA

Fuchs,John ViiV Healthcare USA

Gagnieu,Marie-Claude Hôpital Eduard Herriot France

Gair,Robert Positive Health Services Canada

Garimella,Tushar Bristol-Myers Squibb USA

Garraffo,Rodolphe Hôpital Pasteur France

George,Jomy Clinical Center USA

German,Polina Gilead Sciences USA

Gregoire,Matthieu CHU Nantes France

Gunasekaran,Suvai Northwestern University Feinberg School of Medicine USA

Haas,David Vanderbilt University Medical Center USA

Harrington,Patrick FDA USA

Jimmerson,Leah University of Colorado USA

Jordan,Julie Teva Pharmaceuticals USA

Kakuda,Thomas Alios BioPharma, Inc. USA

Kashuba,Angela UNC Eshelman School of Pharmacy USA

Kern,Steven Bill & Melinda Gates Foundation USA

Khoo,Saye University of Liverpool United Kingdom

Kim,Nancy Merck & Co. USA

King,Jennifer Abbvie USA

Kirby,Brian Gilead Sciences USA

Kiser,Jennifer University of Colorado Denver USA

Klem,Katherine Bristol-Myers Squibb USA

Kong,Harold ViiV Healthcare USA

Koteff,Justin ViiV Healthcare USA

Kottilil,Shyam Institute of Human Virology, USA

Kreutzwiser,Denise University Health Network Canada

Kumar,Parag NIH USA

Lafont,Bertrand Gilead France

Lamorde,Mohammed Infectious Diseases Institute Uganda

Lamoureux,Fabien CHU Rouen France

Landgraf,Nathalie Centre Hospitalier France

Le,Minh Patrick Hôpital Bichat-Claude Bernard France

Lee,Lawrence National University of Singapore Singapore

Leger,Paul Vanderbilt University School of Medicine USA

Lehrman,Sandra Merck USA


HIVHepatitis



Lemaitre,Florian Hopital Pontchaillou - Chu De Rennes France

Liu,Siyu University of Southern California USA

MacBrayne,Christine University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences

USA

Martel,Dominic Centre Hospitalier de l'Université de Montréal Canada

Marzolini,Catia University Hospital Basel Switzerland

Mascolini,Mark Medical Writer USA

Mathias,Anita Gilead Sciences USA

Maubert,Marie Anne Assistance Publique Hôpitaux de Paris France

McAllister,Kevin University of Colorado School of Medicine USA

McIlleron,Helen University of Cape Town South Africa

Merrill,Deanna ViiV Healthcare USA

Metsu,David CHU Toulouse - Purpan France

Mirochnick,Mark Boston University USA

Mogalian,Erik Gilead Sciences USA

Mogalian,Erik Gilead Sciences USA

Moguilnikov,Maria ViiV Healthcare France

Moltó,José Hospital Universitari Germans Trias i Pujol Spain

Monchaud,Caroline Hôpital Dupuytren France

Moore,Katy ViiV Healthcare USA

Mukherjee,Dwaipayan AbbVie USA

Muret,Patrice Hôpital Jean Minjoz France

Naik,Sarjita Gilead Sciences USA

Neant,Nadege Aix-Marseille University France

Owen,Andrew University of Liverpool United Kingdom

Patarroyo,Jimena ViiV Healthcare USA

Patel,Parul ViiV Healthcare USA

Peytavin,Gilles Hopital Bichat Claude Bernard France

Phillips,Elizabeth Vanderbilt University School of Medicine USA

Podany,Anthony University of Nebraska USA

Poirier,Jean-Marie Saint-Antoine University Hospital France

Pope,Camille AbbVie USA

Quaranta,Sylvie Hôpital de la Timone France

Rakhmanina,Natella Children's National Medical Center USA

Ritchings,Corey Bristol-Myers Squibb USA

Rizk,Matthew Merck Sharpe & Dohme Corp., a subsidiary of Merck and Co., Inc. USA

Roberts,Owain University of Liverpool United Kingdom

Robillard,Kevin ViiV Healthcare ULC Canada

Rogatto,Felipe Gilead Sciences Europe Ldt United Kingdom

Rublein,John Gilead Sciences USA

Sampson,Mario Food and Drug Administration USA

Scarsi,Kimberly University of Nebraska USA


HIVHepatitis



Schapiro,Jonathan Sheba Medical Center Israel

Seggev,Michael SeggevM Consulting LLC USA

Seifert,Sharon University of Colorado Denver USA

Seo,Shirley FDA USA

Sevinsky,Heather Bristol-Myers Squibb USA

Shang,Hong The First Affliated Hospital of China Medical University China

Sheehan,Nancy McGill University Health Centre Canada

Siccardi,Marco University of Liverpool United Kingdom

Smolders,Elise Radboud Universitair Medisch Centrum The Netherlands

Solas Chesneau,Caroline Hôpital de la Timone France

Spreen,William ViiV Healthcare USA

Sutton,Kenneth ViiV Healthcare USA

Taburet,Anne-Marie Hôpital Bicêtre France

Teppler,Hedy Merck USA

Terrail,Nicolas Hôpital Lapeyronie France

Thammajaruk,Narukjaporn HIV Netherlands Australia Thailand Research Collaboration (HIV-NAT), Thai Red Cr

Thailand

Therrien,Rachel Centre Hospitalier de l'Université de Montréal Canada

Thompson,Corbin UNC Chapel Hill USA

Trezza,Christine ViiV Healthcare USA

Tseng,Alice Toronto General Hospital Canada

Venisse,Nicolas Centre Hospitalier Universitaire France

Vourvahis,Manoli Pfizer, Inc USA

Weber,Michael University of North Carolina at Chapel Hill USA

Wolford,Dennis Merck Sharpe & Dohme Corp., a subsidiary of Merck and Co., Inc. USA

Yau,Stuart Gilead Sciences Ltd United Kingdom

Yoder,Christian Food and Drug Administration USA

Younis,Islam FDA USA

Zhang,Qingling Alios BioPharma USA

Zhengyu,Xue Parexel International USA

Zhuang,Luning FDA USA


INTERNATIONAL WORKSHOP ON CLINICAL PHARMACOLOGY … · Future: 40 years of Clinical Pharmacology)...

Documents

Transcript of INTERNATIONAL WORKSHOP ON CLINICAL PHARMACOLOGY … · Future: 40 years of Clinical Pharmacology)...